Abstract | BACKGROUND: ETHICS: The protocol was approved by the institutional review board of each study center. Written informed consent will be obtained from all patients before registration, in accordance with the Declaration of Helsinki. METHODS: We performed a systematic literature review and meta-analysis to assess the association between finasteride and prostate cancer. Systematic literature searches were conducted using PubMed, EMBASE, Science Direct/Elsevier, MEDLINE, CNKI, and the Cochrane Library up to October 2018 to identify studies that involved the relationship between finasteride and prostate cancer. Meta-analysis was performed using Review Manager and Stata software. Combined ORs were identified with 95% confidence intervals (95% CI) in a random or fixed effects model. RESULTS: Eight studies were identified, including 54,335 cases of patients that used finasteride and 9197 patients who served as placebo controls. Our results illustrate that there is a significant correlation between finasteride use and prostate cancer with combined ORs of 0.70 [0.51, 0.96]. A significant correlation between finasteride use and high-grade prostate cancer was also observed with combined ORs of 2.10 [1.85, 2.38]. CONCLUSIONS:
|
Authors | Lei Wang, Yonghua Lei, Yanyao Gao, Dong Cui, Qisheng Tang, Ruixiao Li, Dong Wang, Yu Chen, Bo Zhang, He Wang |
Journal | Medicine
(Medicine (Baltimore))
Vol. 99
Issue 15
Pg. e19486
(Apr 2020)
ISSN: 1536-5964 [Electronic] United States |
PMID | 32282699
(Publication Type: Journal Article, Meta-Analysis, Systematic Review)
|
Chemical References |
- 5-alpha Reductase Inhibitors
- Finasteride
|
Topics |
- 5-alpha Reductase Inhibitors
(adverse effects)
- Finasteride
(adverse effects)
- Humans
- Male
- Prostatic Neoplasms
(chemically induced)
|